Pharma News
Radical treatments for difficult times
The economic downturn is only one of many factors forcing the drug industry to rethink its strategy reported Financial Times pharmaceuticals correspondent Mr Andrew Jack in the British Medical Journal. According to him, large drug makers such as AstraZeneca, GlaxoSmithKline, Merck and Pfizer are being forced to adapt at an increasing pace to a range of growing pressures.
API opportunities in biologicals, biosimilars and generics
The active pharmaceutical ingredient (API) market, traditionally dominated by small-molecule drugs, is currently witnessing a rapid shift towards biopharmaceuticals. At the same time, the manufacturing volume outsourced to contract manufacturing firms is on the rise. As plain vanilla generics continue to get highly competitive, API manufacturers are searching for newer avenues such as the production of high-potency APIs to differentiate themselves from competition.
